171 related articles for article (PubMed ID: 31487153)
1. Sugar-Modified Analogs of Auranofin Are Potent Inhibitors of the Gastric Pathogen
Epstein TD; Wu B; Moulton KD; Yan M; Dube DH
ACS Infect Dis; 2019 Oct; 5(10):1682-1687. PubMed ID: 31487153
[No Abstract] [Full Text] [Related]
2. Auranofin and N-heterocyclic carbene gold-analogs are potent inhibitors of the bacteria Helicobacter pylori.
Owings JP; McNair NN; Mui YF; Gustafsson TN; Holmgren A; Contel M; Goldberg JB; Mead JR
FEMS Microbiol Lett; 2016 Jul; 363(14):. PubMed ID: 27279627
[TBL] [Abstract][Full Text] [Related]
3. Potential Anticancer Activity of Auranofin.
Onodera T; Momose I; Kawada M
Chem Pharm Bull (Tokyo); 2019; 67(3):186-191. PubMed ID: 30827998
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationships in a series of auranofin analogues showing remarkable antiproliferative properties.
Landini I; Massai L; Cirri D; Gamberi T; Paoli P; Messori L; Mini E; Nobili S
J Inorg Biochem; 2020 Jul; 208():111079. PubMed ID: 32497830
[TBL] [Abstract][Full Text] [Related]
5. Sublethal concentrations of diverse gold compounds inhibit mammalian cytosolic thioredoxin reductase (TrxR1).
Omata Y; Folan M; Shaw M; Messer RL; Lockwood PE; Hobbs D; Bouillaguet S; Sano H; Lewis JB; Wataha JC
Toxicol In Vitro; 2006 Sep; 20(6):882-90. PubMed ID: 16510263
[TBL] [Abstract][Full Text] [Related]
6. Auranofin inactivates Trichomonas vaginalis thioredoxin reductase and is effective against trichomonads in vitro and in vivo.
Hopper M; Yun JF; Zhou B; Le C; Kehoe K; Le R; Hill R; Jongeward G; Debnath A; Zhang L; Miyamoto Y; Eckmann L; Land KM; Wrischnik LA
Int J Antimicrob Agents; 2016 Dec; 48(6):690-694. PubMed ID: 27839893
[TBL] [Abstract][Full Text] [Related]
7. [Potential Anticancer Activity of Auranofin].
Momose I; Onodera T; Kawada M
Yakugaku Zasshi; 2021; 141(3):315-321. PubMed ID: 33642497
[TBL] [Abstract][Full Text] [Related]
8. Auranofin, a thioredoxin reductase inhibitor, causes platelet death through calcium overload.
Harper MT
Platelets; 2019; 30(1):98-104. PubMed ID: 29194002
[TBL] [Abstract][Full Text] [Related]
9. Repurposing of the gold drug auranofin and a review of its derivatives as antibacterial therapeutics.
Liu Y; Lu Y; Xu Z; Ma X; Chen X; Liu W
Drug Discov Today; 2022 Jul; 27(7):1961-1973. PubMed ID: 35192926
[TBL] [Abstract][Full Text] [Related]
10. Gold Nanoclusters as Nanoantibiotic Auranofin Analogues.
Ndugire W; Raviranga NGH; Lao J; Ramström O; Yan M
Adv Healthc Mater; 2022 May; 11(9):e2101032. PubMed ID: 34350709
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial thioredoxin reductase inhibition by gold(I) compounds and concurrent stimulation of permeability transition and release of cytochrome c.
Rigobello MP; Scutari G; Folda A; Bindoli A
Biochem Pharmacol; 2004 Feb; 67(4):689-96. PubMed ID: 14757168
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of thioredoxin reductase by auranofin induces apoptosis in adriamycin-resistant human K562 chronic myeloid leukemia cells.
Liu JJ; Liu Q; Wei HL; Yi J; Zhao HS; Gao LP
Pharmazie; 2011 Jun; 66(6):440-4. PubMed ID: 21699084
[TBL] [Abstract][Full Text] [Related]
13. Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis.
Harbut MB; Vilchèze C; Luo X; Hensler ME; Guo H; Yang B; Chatterjee AK; Nizet V; Jacobs WR; Schultz PG; Wang F
Proc Natl Acad Sci U S A; 2015 Apr; 112(14):4453-8. PubMed ID: 25831516
[TBL] [Abstract][Full Text] [Related]
14. The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax/Bak-dependent process that involves peroxiredoxin 3 oxidation.
Cox AG; Brown KK; Arner ES; Hampton MB
Biochem Pharmacol; 2008 Oct; 76(9):1097-109. PubMed ID: 18789312
[TBL] [Abstract][Full Text] [Related]
15. Potential of fumarate reductase as a novel therapeutic target in Helicobacter pylori infection.
Ge Z
Expert Opin Ther Targets; 2002 Apr; 6(2):135-46. PubMed ID: 12223076
[TBL] [Abstract][Full Text] [Related]
16. The mechanism of action of auranofin analogs in
Maydaniuk DT; Martens B; Iqbal S; Hogan AM; Lorente Cobo N; Motnenko A; Truong D; Liyanage SH; Yan M; Prehna G; Cardona ST
Microbiol Spectr; 2024 Feb; 12(2):e0320123. PubMed ID: 38206016
[TBL] [Abstract][Full Text] [Related]
17.
Huang Y; Hang X; Jiang X; Zeng L; Jia J; Xie Y; Li F; Bi H
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30936098
[No Abstract] [Full Text] [Related]
18. Repurposing of auranofin: Thioredoxin reductase remains a primary target of the drug.
Zhang X; Selvaraju K; Saei AA; D'Arcy P; Zubarev RA; Arnér ES; Linder S
Biochimie; 2019 Jul; 162():46-54. PubMed ID: 30946948
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triple-negative breast cancer.
Raninga PV; Lee AC; Sinha D; Shih YY; Mittal D; Makhale A; Bain AL; Nanayakarra D; Tonissen KF; Kalimutho M; Khanna KK
Int J Cancer; 2020 Jan; 146(1):123-136. PubMed ID: 31090219
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of auranofin-induced apoptosis in MCF-7 human breast cells by selenocystine, a synergistic inhibitor of thioredoxin reductase.
Liu C; Liu Z; Li M; Li X; Wong YS; Ngai SM; Zheng W; Zhang Y; Chen T
PLoS One; 2013; 8(1):e53945. PubMed ID: 23342042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
